About dabrafenib
BRAF kinase inhibitor
Used for
- Treats certain cancers with a BRAF V600 mutation, including melanoma, lung cancer, and thyroid cancer.
- Used alone or with trametinib, depending on the cancer.
Usual adult dose
Usually 150 mg twice daily; dosing depends on cancer and whether combined with trametinib.
Usual dose in children
For selected cancers, usually 2 mg/kg twice daily, maximum 150 mg per dose; specialist dosing varies by age and weight.
Common side effects
- Fever and chills
- Rash and other skin problems
- Headache, tiredness, or nausea
- High blood sugar or liver-enzyme changes
Important warnings
- Only for cancers with a confirmed BRAF V600 mutation.
- Can cause serious fever, bleeding, heart problems, or eye problems.
- May increase risk of new skin cancers; regular skin checks are needed.
- Dispersible tablets are prepared as an oral suspension; do not swallow them whole.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for at least 2 weeks afterward.
Breastfeeding
Do not breastfeed during treatment and for 2 weeks after the final dose.
Interactions
- Hormonal contraceptives may work less reliably; use an additional nonhormonal method.
- Can interact with warfarin and medicines affected by CYP enzymes.
- St John’s wort and some seizure medicines can reduce dabrafenib levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.